# Thomas W. Flaig

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/thomas-w-flaig/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,614 |
| Field | Bladder and Urothelial Cancer Treatments |
| h-index | 54 |
| i10-index | 138 |
| Last Known Institution | University of Colorado Cancer Center |
| OpenAlex ID | https://openalex.org/A5088312939 |
| ORCID iD | https://orcid.org/0000-0001-6145-9040 |
| Works | 398 |

## Researcher papers

- [Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy](https://scholariq.org/papers/increased-survival-with-enzalutamide-in-prostate-cancer-after-chemotherapy/)
- [Abiraterone and Increased Survival in Metastatic Prostate Cancer](https://scholariq.org/papers/abiraterone-and-increased-survival-in-metastatic-prostate-cancer/)
- [Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy](https://scholariq.org/papers/abiraterone-in-metastatic-prostate-cancer-without-previous-chemotherapy/)
- [Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology](https://scholariq.org/papers/bladder-cancer-version-1-2026-nccn-clinical-practice-guidelines-in-oncology/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma](https://scholariq.org/papers/phase-ii-randomized-trial-comparing-sequential-first-line-everolimus-and-second/)
- [NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022](https://scholariq.org/papers/nccn-guidelines-insights-bladder-cancer-version-2-2022/)
- [Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/bladder-cancer-version-5-2017-nccn-clinical-practice-guidelines-in-oncology/)
- [Bladder Cancer, Version 3.2024](https://scholariq.org/papers/bladder-cancer-version-3-2024/)

## Researcher topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Researcher university

- [University of Colorado Cancer Center](https://scholariq.org/institutions/university-of-colorado-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.